---
schema_version: "secwatch.filing_event.v1"
accession: "0001819790-22-000033"
form_type: "8-K"
ticker: "TARS"
cik: "0001819790"
company_name: "Tarsus Pharmaceuticals, Inc."
filed_at: "2022-10-12T23:59:59+00:00"
generated_at: "2026-06-23T04:08:49.095026+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Tarsus expands board to nine, appoints Scott Morrison, plans Chairperson transition

## Summary
- Scott Morrison appointed to Board as Class III director effective Oct 6, 2022, and as Audit Committee Chair.
- Board expanded from eight to nine directors; new Commercial Committee formed with Morrison, Yarno, Yeu-Lin, Crane (Chair).
- Michael Ackermann expected to transition off Board by end of 2022; Bobak Azamian to become Chairperson, Wendy Yarno Lead Independent Director.
- Morrison receives initial equity grant: option for 14,000 shares plus 4,000 RSUs.
- Morrison is independent under Nasdaq standards and qualifies as audit committee financial expert.

## SEC filing metadata
- accession: 0001819790-22-000033
- form_type: 8-K
- ticker: TARS
- cik: 0001819790
- company_name: Tarsus Pharmaceuticals, Inc.
- filed_at: 2022-10-12T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819790/000181979022000033/0001819790-22-000033-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819790/000181979022000033/tars-20221006.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001819790-22-000033
- JSON: https://secwatch.observer/filing/0001819790-22-000033.json
- Plain text: https://secwatch.observer/filing/0001819790-22-000033.txt

## Key facts
- Executive change
  Scott Morrison was appointed as Director at Tarsus Pharmaceuticals, Inc..
  - Action: appointed
  - Role: Director
  source text: expanded the size of the Board from eight to nine directors and appointed Scott Morrison to the Board, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819790/000181979022000033/0001819790-22-000033-index.htm
- Executive change
  Bobak Azamian was appointed as Chairperson of the Board at Tarsus Pharmaceuticals, Inc..
  - Action: will be appointed
  - Role: Chairperson of the Board
  source text: Bobak Azamian, the Company’s Chief Executive Officer and current member of the Board will be appointed as Chairperson of the Board
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819790/000181979022000033/0001819790-22-000033-index.htm
- Executive change
  Wendy Yarno was appointed as Lead Independent Director at Tarsus Pharmaceuticals, Inc..
  - Action: will be appointed
  - Role: Lead Independent Director
  source text: Wendy Yarno, current member of the Board, will be appointed as Lead Independent Director
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819790/000181979022000033/0001819790-22-000033-index.htm
- Executive change
  Michael Ackermann changed role as Chairperson of the Board at Tarsus Pharmaceuticals, Inc..
  - Action: expected to transition off
  - Role: Chairperson of the Board
  source text: Michael Ackermann, the Chairperson of the Board, expected to transition off the Board by the end of the 2022 calendar year
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819790/000181979022000033/0001819790-22-000033-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.